Business Description
Poxel SA
ISIN : FR0012432516
Total Employee Number:
5Compare
Compare
Traded in other countries / regions
POXEL.France0RA2.UK7PO.GermanyPXXLF.USA IPO Date
2015-02-12Description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | -12.28 | |||||
Debt-to-Equity | -0.24 | |||||
Debt-to-EBITDA | -1.56 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -4.21 | |||||
Beneish M-Score | 0.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -33.3 | |||||
3-Year EBITDA Growth Rate | 29.4 | |||||
3-Year EPS without NRI Growth Rate | 23.4 | |||||
3-Year FCF Growth Rate | 30.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.89 | |||||
9-Day RSI | 46.09 | |||||
14-Day RSI | 43.62 | |||||
3-1 Month Momentum % | -22.6 | |||||
6-1 Month Momentum % | -5.23 | |||||
12-1 Month Momentum % | -62.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.26 | |||||
Quick Ratio | 0.26 | |||||
Cash Ratio | 0.11 | |||||
Days Sales Outstanding | 104.44 | |||||
Days Payable | 151.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.2 | |||||
Shareholder Yield % | 194.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.02 | |||||
Operating Margin % | -22.93 | |||||
Net Margin % | -178.45 | |||||
EBITDA Margin % | -122.89 | |||||
FCF Margin % | 10.66 | |||||
OCF Margin % | 10.66 | |||||
ROA % | -160.6 | |||||
ROIC % | -9.83 | |||||
3-Year ROIIC % | -156.39 | |||||
ROC (Joel Greenblatt) % | -118012.5 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.38 | |||||
Price-to-Free-Cash-Flow | 16.76 | |||||
Price-to-Operating-Cash-Flow | 16.76 | |||||
EV-to-EBIT | -2.63 | |||||
EV-to-EBITDA | -2.64 | |||||
EV-to-Revenue | 3.25 | |||||
EV-to-FCF | 30.75 | |||||
Price-to-GF-Value | 0.16 | |||||
Earnings Yield (Greenblatt) % | -37.86 | |||||
FCF Yield % | 6.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Poxel SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.657 | ||
| EPS (TTM) (€) | -0.26 | ||
| Beta | 46.6134 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 71.04 | ||
| Volatility % | 82.26 | ||
| 14-Day RSI | 43.62 | ||
| 14-Day ATR (€) | 0.006392 | ||
| 20-Day SMA (€) | 0.206065 | ||
| 12-1 Month Momentum % | -62.82 | ||
| 52-Week Range (€) | 0.1944 - 0.653 | ||
| Shares Outstanding (Mil) | 61.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Poxel SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Poxel SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 125 days | ||
| Fourth quarter earnings conference call for 2025 | 2026-10-16 18:00 | In 105 days | ||
| Fourth quarter earnings results for 2025 | 2026-10-16 | In 104 days | ||
| Second quarter earnings conference call for 2026 | 2026-09-23 | In 81 days | ||
| Second quarter earnings results for 2026 | 2026-09-23 | In 81 days | ||
| General meeting for 2025 | 2026-07-23 | In 19 days | ||
| Annual report for 2025 | 2026-06-15 | 0.20 (+0.00%) | ||
| General meeting for 2024 | 2025-12-11 | 0.22 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 0.32 (+0.00%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-10-16 18:00 | 0.42 (+0.00%) |
Show
Entries
Poxel SA Frequently Asked Questions
What is Poxel SA(FRA:7PO)'s stock price today?
The current price of FRA:7PO is €0.20. The 52 week high of FRA:7PO is €0.65 and 52 week low is €0.19.
When is next earnings date of Poxel SA(FRA:7PO)?
The next earnings date of Poxel SA(FRA:7PO) is 2026-09-23 Est..
Does Poxel SA(FRA:7PO) pay dividends? If so, how much?
Poxel SA(FRA:7PO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Poxel SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers